Telesis Bio, Inc. (TBIO)

NASDAQ: TBIO · IEX Real-Time Price · USD
3.355
-0.235 (-6.55%)
At close: Jul 15, 2024, 3:43 PM
3.420
+0.065 (1.94%)
After-hours: Jul 15, 2024, 7:29 PM EDT
-6.55%
Market Cap 5.62M
Revenue (ttm) 24.63M
Net Income (ttm) -47.13M
Shares Out 1.67M
EPS (ttm) -28.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,306
Open 3.600
Previous Close 3.590
Day's Range 3.325 - 4.000
52-Week Range 3.025 - 29.340
Beta 1.74
Analysts Hold
Price Target n/a
Earnings Date Aug 8, 2024

About TBIO

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 18, 2021
Employees 127
Stock Exchange NASDAQ
Ticker Symbol TBIO
Full Company Profile

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.

Financial Statements

News

Telesis Bio Reports First Quarter 2024 Financial Results

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flex...

2 months ago - GlobeNewsWire

Telesis Bio Announces Reverse Stock Split

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through ...

2 months ago - GlobeNewsWire

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the comme...

3 months ago - GlobeNewsWire

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fl...

3 months ago - GlobeNewsWire

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fle...

5 months ago - GlobeNewsWire

Telesis Bio Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter o...

8 months ago - GlobeNewsWire

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio  (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 ...

8 months ago - GlobeNewsWire

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA

New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days

9 months ago - GlobeNewsWire

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology Workstation N...

10 months ago - GlobeNewsWire

Telesis Bio Appoints William J. Kullback Chief Financial Officer

SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Off...

11 months ago - GlobeNewsWire

Telesis Bio Reports Second Quarter 2023 Financial Results

-- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year -- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year

1 year ago - GlobeNewsWire

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 ...

1 year ago - GlobeNewsWire

Telesis Bio to Present at Jefferies Healthcare Conference 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of...

1 year ago - GlobeNewsWire

Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

1 year ago - GlobeNewsWire

Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the ...

1 year ago - GlobeNewsWire

Telesis Bio Secures Financing of $28.0 Million

Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners SAN DIE...

1 year ago - GlobeNewsWire

Telesis Bio to Present at SynBioBeta 2023

Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and ...

1 year ago - GlobeNewsWire

Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit

New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit...

1 year ago - GlobeNewsWire

Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit

New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit Enables Automation of...

1 year ago - GlobeNewsWire

Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)

Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications

1 year ago - GlobeNewsWire

Telesis Bio Reports First Quarter 2023 Financial Results

-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synth...

1 year ago - GlobeNewsWire

Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 ...

1 year ago - GlobeNewsWire

Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up

New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation New Releases Extend the BioXp® Select Product...

1 year ago - GlobeNewsWire

Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21

1 year ago - GlobeNewsWire

Telesis Bio to Present at Festival of Biologics Conference

Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO and ...

1 year ago - GlobeNewsWire